Head-to-head comparison
Klinic vs Sprout Health
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Klinic is a LegitScript-certified multi-condition telehealth platform prescribing brand-name GLP-1 medications—Wegovy (semaglutide) and Zepbound (tirzepatide)—to patients across all 50 U.S.
Marked down on: Brand-name meds are costly self-pay: Wegovy ~$499/month, Zepbound ~$299/month (med cost alone; consult extra)
Desk Score
A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.
$299/mo sema · $349/mo tirz · Verified August 2026
Marked down on: FDA issued Sprout Health Partners LLC dba Sprout Health a warning letter in September 2025; the letter is public in FDA's warning-letter database
FDAWarning letter issued to Sprout Health Partners LLC dba Sprout Health in September 2025. See the FDA warning-letter database.
Sprout Health takes this head-to-head with the higher Desk Score, 86/100 (B) against 63/100 (C) for Klinic. Klinic still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Klinic
63/100
C
Sprout Health
86/100
B
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Klinic | Sprout Health |
|---|---|---|
| Semaglutide | Not listed on Klinic's site (checked July 2026) | $299/mo$299/mo month-to-month (compounded; $149 for the first month with code FIRST150; monthly, 3-month or 6-month subscriptions) — brand Wegovy from $1,799/mo |
| Tirzepatide | Not listed on Klinic's site (checked July 2026) | $349/mo$349/mo month-to-month (compounded; $199 for the first month, which is the same $150 off) — brand Zepbound from $1,999/mo |
| Coverage | Not listed on Klinic's site (checked July 2026) | Not listed on Sprout Health's site (checked August 2026) |
| Brand-name | Yes | Yes |
| Oral option | Injectable only | Injectable only |
| Best for | Brand-name Wegovy & Zepbound through insurance (Medicare/Medicaid OK) or self-pay, all 50 states. | Patients who want a low compounded entry price but the option of brand-name Wegovy or Zepbound on the same account, with minimal onboarding. |
| Desk Score | 63/100C | 86/100B |
The verdict
Desk pick — Sprout HealthSprout Health takes this head-to-head with the higher Desk Score, 86/100 (B) against 63/100 (C) for Klinic. Klinic still holds its ground where its strengths line up with yours.
Choose Klinic if…
Brand-name Wegovy & Zepbound through insurance (Medicare/Medicaid OK) or self-pay, all 50 states.
Choose Sprout Health if…
Patients who want a low compounded entry price but the option of brand-name Wegovy or Zepbound on the same account, with minimal onboarding.
$299/mo sema · $349/mo tirz
FDAWarning letter issued to Sprout Health Partners LLC dba Sprout Health in September 2025. See the FDA warning-letter database.
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Klinic · Sprout Health.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs Klinic
- CoreAge Rx vs Sprout Health
- Eden vs Klinic
- Sprout Health vs Vytora Health
- Klinic vs Pallas Health
- Amazon One Medical vs Sprout Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.